Ascent Industries Co. Q2 FY2025 earnings call

• Successfully divested Tubular segment, now a pure-play specialty chemical company.
• Repurchased nearly 6% of outstanding shares.
• Sequential improvements in revenue, gross profit, margin, and adjusted EBITDA.
• Operations team drove momentum with labor, overhead, and production variances improving over $1.2 million year-over-year, service levels at all-time highs.
• Process modifications drove 5% yield improvement, unlocking $250,000 in annualized gross profit and reducing cycle times.
• Strategic sourcing reduced raw material costs, with 95% of revenue supported by domestically produced raw materials.
• Secured over $3.1 million of annualized new revenue at 29% gross margin, spanning multiple markets.
• SG&A expenses flat but return on spend changed with measurable results from new commercial wins, stronger margins, etc.

In Q2, revenue was $18.7 million, up sequentially by $817,000 but down from prior year $21.4 million due to market softness. Gross profit rose $1.8 million from Q1 and $2.1 million year-over-year. Gross margin expanded to 26.1%, up 888 basis points sequentially and 1,298 basis points year-over-year. Adjusted EBITDA was a loss of $335,000 in the quarter but improved when excluding certain costs. The Tubular segment was fully divested, with the remaining idle facility in Munhall being a $2.1 million annualized headwind to adjusted EBITDA.

• Confident in growing to $120-130 million in top line within existing asset base.
• Selling project pipeline increased by $25 million, spread across market segments with mix of product sales and custom manufacturing.
• Plan to pursue smaller M&A transactions first to demonstrate growth and cost synergies before larger deals.
• M&A expected to be in 6x to 8x post-OpEx synergies range, pre-synergies up to 8x-9x.

• Broader market softness impacting revenue.
• Remaining idle tubular facility in Munhall as a $2.1 million annualized headwind to adjusted EBITDA.
• Potential risks associated with M&A integration if not executed properly.

Q: What sort of revenue number are you contemplating for the 2030 adjusted EBITDA margin target?

A: Confident in getting to $120 million to $130 million of top line within existing asset base.

Q: How should we think about the near to intermediate-term new business pipeline?

A: Selling project pipeline increased by $25 million, spread across 4-5 market segments, mix of product sales and high-value custom manufacturing.

Q: Has the executive management equity compensation plan been presented to the Board?

A: Broader equity program is at final stages, existing program for CEO and CFO, share buyback not related to equity program for senior leaders.

Q: What's the catalyst to get a higher multiple?

A: Growth, growth, growth; focusing on organic and inorganic growth.

Q: Do you think a return to profitability is in the cards for third or fourth quarter?

A: Working towards it, excluding Munhall aspect, effectively there but aiming for larger aspirations.

Q: Thoughts on M&A discipline?

A: Will pursue smaller transactions first to demonstrate synergies, not doing deals for sake of doing deals, looking for assets in 6x to 8x post-OpEx synergies range pre-synergies up to 8x-9x